Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-73-222-0700
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees86
OptionableNot Optionable
Rosetta Genomics (NASDAQ:ROSG) Frequently Asked Questions
What is Rosetta Genomics' stock symbol?
Rosetta Genomics trades on the NASDAQ under the ticker symbol "ROSG."
How were Rosetta Genomics' earnings last quarter?
Rosetta Genomics (NASDAQ:ROSG) posted its quarterly earnings results on Thursday, May, 19th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.02. The medical research company had revenue of $2.60 million for the quarter, compared to analysts' expectations of $3.36 million. View Rosetta Genomics' Earnings History.
What price target have analysts set for ROSG?
0 Wall Street analysts have issued 1-year price targets for Rosetta Genomics' shares. Their predictions range from $0.02 to $0.02. On average, they expect Rosetta Genomics' share price to reach $0.02 in the next year. This suggests that the stock has a possible downside of 95.3%. View Analyst Price Targets for Rosetta Genomics.
Has Rosetta Genomics been receiving favorable news coverage?
News headlines about ROSG stock have been trending negative on Thursday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Rosetta Genomics earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the next several days.
Who are some of Rosetta Genomics' key competitors?
Some companies that are related to Rosetta Genomics include Advanced Accelerator Application (AAAP), Aerpio Pharmaceuticals (ARPO), AgeX Therapeutics (AGE), American Oriental Bioengineering (AOBI), Anthera Pharmaceuticals (ANTH), Aralez Pharmaceuticals (ARLZ), Argos Therapeutics (ARGS), ARMO Biosciences (ARMO), Biostar Pharmaceuticals (BSPM), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO) and Egalet (EGLT).
Who are Rosetta Genomics' key executives?
Rosetta Genomics' management team includes the folowing people:
- Mr. Kenneth A. Berlin, Pres & CEO (Age 54)
- Mr. Ron Kalfus CPA, Chief Financial Officer (Age 44)
- Mr. Oded Biran Adv., Gen. Counsel and Sec. (Age 39)
- Dr. Eti Meiri Ph.D., VP of Research (Age 50)
- Ms. Ana C. Ward Esq., M.S.,M.B.A., Exec. VP of Legal and Corp. Devel.
How do I buy shares of Rosetta Genomics?
Shares of ROSG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rosetta Genomics' stock price today?
One share of ROSG stock can currently be purchased for approximately $0.4299.
What is Rosetta Genomics' official website?
How can I contact Rosetta Genomics?
Rosetta Genomics' mailing address is 10 PLAUT STREET SCIENCE PARK, REHOVOT L3, 76706. The medical research company can be reached via phone at 972-73-222-0700 or via email at [email protected]
MarketBeat Community Rating for Rosetta Genomics (NASDAQ ROSG)
MarketBeat's community ratings are surveys of what our community members think about Rosetta Genomics and other stocks. Vote "Outperform" if you believe ROSG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ROSG will underperform the S&P 500 over the long term. You may vote once every thirty days.
